Literature DB >> 9671952

Clinical usefulness of CA-19-9 in pancreatic carcinoma.

A Nakao1, K Oshima, S Nomoto, S Takeda, T Kaneko, T Ichihara, T Kurokawa, T Nonami, H Takagi.   

Abstract

Preoperative and postoperative serum levels of carbohydrate antigen-(CA)19-9 in 148 patients with carcinoma of the pancreas were studied. All 18 patients with carcinoma of the pancreas of Stage I, II, and III were resectable, and their pre-operative serum levels of CA-19-9 were under 1,344 U/ml. Pre-operative serum levels of CA-19-9 in patients with Stage IV ranged widely between 5 and 32,240 U/ml. The postoperative survival rate was significantly superior in patients (n = 15) whose CA-19-9 pre-operative serum levels were less than 2,000 U/ml compare to those (n = 64) whose levels were over that level. Fifteen resectable patients who showed serum levels of CA-19-9 over 2,000 U/ml pre-operatively died within 2 years postoperatively due to recurrence, especially by liver metastasis in spite of aggressive surgery. Intraoperative quick immunostaining of CA-19-9 and carcinoembryonic antigen (CEA) was useful to diagnose intrapancreatic carcinoma development on frozen sections of cut margin of the pancreas and also useful in abdominal washing cytology combined with conventional staining.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671952     DOI: 10.1002/(sici)1098-2388(199807/08)15:1<15::aid-ssu4>3.0.co;2-z

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  12 in total

Review 1.  Oncological problems in pancreatic cancer surgery.

Authors:  Akimasa Nakao; Tsutomu Fujii; Hiroyuki Sugimoto; Naohito Kanazumi; Shuji Nomoto; Yasuhiro Kodera; Soichiro Inoue; Shin Takeda
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

2.  Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma.

Authors:  Joshua G Barton; John P Bois; Michael G Sarr; Christina M Wood; Rui Qin; Kristine M Thomsen; Michael L Kendrick; Michael B Farnell
Journal:  J Gastrointest Surg       Date:  2009-09-09       Impact factor: 3.452

3.  The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  J Gastrointest Oncol       Date:  2012-06

4.  Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma.

Authors:  Cristina R Ferrone; Dianne M Finkelstein; Sarah P Thayer; Alona Muzikansky; Carlos Fernandez-delCastillo; Andrew L Warshaw
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

5.  Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  Indian J Surg Oncol       Date:  2011-02-17

6.  Very high serum CA 19-9 levels: a contraindication to pancreaticoduodenectomy?

Authors:  O Turrini; C M Schmidt; J Moreno; P Parikh; J M Matos; M G House; N J Zyromski; A Nakeeb; H A Pitt; K D Lillemoe
Journal:  J Gastrointest Surg       Date:  2009-05-21       Impact factor: 3.452

7.  Targeting anticancer drug delivery to pancreatic cancer cells using a fucose-bound nanoparticle approach.

Authors:  Makoto Yoshida; Rishu Takimoto; Kazuyuki Murase; Yasushi Sato; Masahiro Hirakawa; Fumito Tamura; Tsutomu Sato; Satoshi Iyama; Takahiro Osuga; Koji Miyanishi; Kohichi Takada; Tsuyoshi Hayashi; Masayoshi Kobune; Junji Kato
Journal:  PLoS One       Date:  2012-07-11       Impact factor: 3.240

8.  The prognostic and predictive value of serum CA19.9 in pancreatic cancer.

Authors:  J L Humphris; D K Chang; A L Johns; C J Scarlett; M Pajic; M D Jones; E K Colvin; A Nagrial; V T Chin; L A Chantrill; J S Samra; A J Gill; J G Kench; N D Merrett; A Das; E A Musgrove; R L Sutherland; A V Biankin
Journal:  Ann Oncol       Date:  2012-01-11       Impact factor: 32.976

9.  Preoperative predictors for early recurrence of resectable pancreatic cancer.

Authors:  Kohei Nishio; Kenjiro Kimura; Ryosuke Amano; Sadaaki Yamazoe; Go Ohrira; Bunzo Nakata; Kosei Hirakawa; Masaichi Ohira
Journal:  World J Surg Oncol       Date:  2017-01-10       Impact factor: 2.754

10.  Nomograms predict long-term survival for patients with periampullary adenocarcinoma after pancreatoduodenectomy.

Authors:  Chaobin He; Yize Mao; Jun Wang; Fangting Duan; Xiaojun Lin; Shengping Li
Journal:  BMC Cancer       Date:  2018-03-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.